Keyphrases
11β-hydroxysteroid Dehydrogenase
100%
Cortisone
61%
Cortisol
60%
Pharmacokinetics
51%
5α-reductase
48%
Reductase Activity
48%
Hydroxysteroid Dehydrogenase
48%
Insulin Resistance
32%
Type 2 Diabetes Mellitus (T2DM)
32%
Production Rate
32%
Prednisolone
32%
Type 2 Diabetes Prevention
30%
Pharmacodynamics
30%
Insulin Sensitivity
29%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
28%
Adipose Tissue
27%
Myotubes
26%
Dual-release Hydrocortisone
24%
Proof of Mechanism
24%
Cynomolgus Monkey
24%
Steroid Production
24%
Adrenocortical Cancer
24%
Mitotane
24%
Secreted Frizzled-related Protein 2
24%
DHCR7
24%
Sterol Reductase
24%
Smith-Lemli-Opitz Syndrome
24%
Activity Biomarkers
24%
Weight Loss
24%
Dehydrogenase Activity
24%
Impaired Glucose Tolerance
24%
Insulin Sensitizers
24%
Glucose-insulin System
24%
HSD1
24%
Glucocorticoid Receptor
24%
Amides
24%
Vascular Endothelial Growth Factor Expression
24%
Amino
24%
Fetus
24%
Intramyocellular
24%
Adiposity
24%
Pregnant Rats
24%
MS Method
24%
SFRP2
24%
Adverse Effects
24%
Sulfonic Acid
24%
25(OH)D3
24%
High-throughput
24%
Cyano
24%
Vitamin D
24%
Protein Metabolism
24%
Local Inflammation
24%
Biphenyl
24%
Simultaneous Analysis
24%
Protein Degradation
24%
Protein Synthesis
24%
Human Myotubes
22%
Prednisone
22%
Type I Inhibitor
22%
Glucocorticoid Excess
20%
Tetrahydrocortisol
18%
8-Dehydrocholesterol
18%
Immediate Release
18%
Steroid Synthesis
18%
11-dehydrocorticosterone
18%
Corticosterone
18%
Cushing's Syndrome
17%
Endogenous Glucocorticoids
17%
Muscle Wasting
17%
Urinary Free Cortisol
15%
Obesity
14%
Cancer Patients
12%
Myoblast Proliferation
12%
Hydrocortisone
12%
Maternal Cholesterol
12%
Oral Dose
12%
Enzyme Activity
12%
Metabolic Syndrome
12%
Fetoplacental
12%
Vitamin D Metabolites
12%
Phosphorylation
12%
Hydroxyl Group
12%
MRNA Expression
12%
Secretion Rate
10%
Oral Glucose Tolerance Test
10%
Metabolic Pathway
10%
Cortisol Level
9%
Molecular Mechanism
9%
Serum Cortisol
9%
Fat Mass
8%
Myopathy
8%
Targeted Inhibition
8%
Classical Action
8%
Glucose Production
8%
Design Drugs
8%
Rodents
8%
Receptor Activation
8%
Obesity Type
8%
Global Epidemic
8%
Rodent Studies
8%
Novel Treatments
8%
Mineralocorticoid
8%
Simple Obesity
8%
Low Glucose
8%
Therapeutic Strategies
8%
Atherogenesis
8%
Lipid Profile
8%
Vitamin D Status
8%
25-hydroxyvitamin D3
8%
Metabolism
6%
Tissue Interstitial Fluid
6%
Glycerol Content
6%
Glucocorticoid Metabolism
6%
24-hour Urine Collection
6%
TNF-Tg Mice
6%
Inflammation
6%
Secondary Adrenal Insufficiency
6%
Progesterone Production
6%
Mstn
6%
Human Myoblasts
6%
Protein Reduction
6%
7-ketocholesterol
6%
Pregnanolone
6%
Maternal Urine
6%
Normal Cholesterol
6%
Oral Prednisone
6%
Maximum Inhibition
6%
Clinical Trials Unit
6%
Generation Study
6%
Corticosteroid-binding Globulin
6%
Intracrine
6%
Multiple Dose
6%
Tolerability
6%
Healthy Volunteers
6%
Urinary Free Cortisone
6%
Dose Effect
6%
Tetrahydrocortisone
6%
Urinary Metabolites
6%
Promising Target
6%
Activity in Vivo
6%
Metabolite Ratios
6%
Placebo-controlled
6%
Oral Administration
6%
Atrophy
6%
Mutant Mice
6%
C2C12
6%
Clinical Features
6%
Proliferative Activity
6%
Androgen Metabolites
6%
Skeletal muscle Atrophy
6%
Human Pregnancy
6%
Muscle Mass
6%
Wild Mice
6%
Mouse Model
6%
Protein Homeostasis
6%
Almost Normal
6%
Skeletal muscle
6%
Reductase
6%
Health Burden
6%
Muscle Protein
6%
Metabolic Processes
6%
Gestational Day
6%
Hydroxylation
6%
Forkhead Box O3 (FOXO3)
6%
Progesterone Metabolites
6%
Mammalian Target of Rapamycin (mTOR)
6%
Adverse Metabolic Effects
6%
Insulin-like Growth factor-1
6%
4E-BP1
6%
Estriol
6%
MuRF1
6%
Atrogin-1
6%
Unsaturation
6%
Receptor Modulation
6%
C-19
6%
Hydroxylated
6%
During Pregnancy
6%
Muscle Size
6%
Human Serum
5%
Insulin Level
5%
Recombinant
5%
Abdominal Adipose Tissue
5%
Insulin Secretion
5%
Pharmacology, Toxicology and Pharmaceutical Science
Glucocorticoid
97%
11beta Hydroxysteroid Dehydrogenase 1
93%
Hydrocortisone
83%
Cortisone
53%
Pharmacokinetics
49%
Steroid 5alpha Reductase
48%
Non Insulin Dependent Diabetes Mellitus
40%
Prednisolone
32%
Insulin Resistance
30%
Pharmacodynamics
30%
Biological Marker
28%
Prednisone
28%
Modified Release
24%
Macaca fascicularis
24%
Mitotane
24%
Impaired Glucose Tolerance
24%
Malignant Neoplasm
24%
11beta Hydroxysteroid Dehydrogenase
24%
Carboxamide
24%
Sulfonic Acid
24%
Hydroxysteroid Dehydrogenase
24%
Biphenyl
24%
Vitamin D
24%
Glucocorticoid Receptor
20%
Tetrahydrocortisol
18%
Clinical Study
18%
Cushing Syndrome
13%
Dehydrocorticosterone
12%
Corticosterone
12%
Metabolic Syndrome X
10%
Normal Human
9%
Diseases
9%
Calcifediol
8%
Muscle Atrophy
8%
Messenger RNA
8%
Tolerability
6%
Placebo
6%
Atherogenesis
6%
Drug Development
6%
Clinical Research
6%
Tetrahydrocortisone
6%
11beta Hydroxysteroid Dehydrogenase 2
6%
Mineralocorticoid
6%
Medicine and Dentistry
Glucocorticoid
77%
Adipose Tissue
48%
Steroid 5alpha Reductase
48%
Hydrocortisone
46%
11beta Hydroxysteroid Dehydrogenase 1
45%
Maturity Onset Diabetes of the Young
34%
Insulin Resistance
30%
Hydrocortisone Release
27%
Insulin Sensitivity
24%
Sensitization
24%
Impaired Glucose Tolerance
24%
Mitotane
24%
Malignant Neoplasm
24%
Hydroxysteroid Dehydrogenase
24%
Adverse Effect
24%
Tumor Necrosis Factor
21%
Secretion (Process)
18%
Clinical Study
18%
Cortisone
15%
Rodent Study
12%
Glucocorticoid Receptor
12%
Muscle Atrophy
10%
Glucose Tolerance
10%
Interstitial Fluid
9%
Cushing Syndrome
9%
Myotube
6%
Research Design
6%
Gluconeogenesis
6%
Tetrahydrocortisol
6%
Atherogenesis
6%
Metabolic Syndrome
6%
Mineralocorticoid
6%
11beta Hydroxysteroid Dehydrogenase 2
6%
Target Tissue
6%